Literature DB >> 22360566

An Australian perspective.

Anthony J Smith1.   

Abstract

Discussing the future of UK clinical pharmacology, eight Australasian clinical pharmacologists emphasized the need to make the discipline 'indispensable' in key areas. The visibility of clinical pharmacology in Australasia has been improved by working with the Consumers' Health Forum in Australia in the construction of the national Policy on Quality Use of Medicines and, later, of the formal National Medicines Policy. Our expertise in clinical pharmacology, combined with the Health Forum's political skills, proved a potent force for launching these policies. A second example was the construction of the national prescribing curriculum in partnership with the National Prescribing Service. This is being used in all medical schools with senior students. At a local level we found that taking over clinical toxicology services (that other clinicians wanted to jettison) provided a stimulus to clinical research and later the formation of a productive subgroup to study the special problems of envenomation. Fourthly, we note that no clinical pharmacology unit in UK is designated as a WHO collaborating centre. Considerable difference can be made to national problems with medicines by clinical pharmacologists willing to work for periods within developing countries. This has given a greater profile to several groups in Australia. The principle of stepping out of conventional settings and actively seeking collaboration with other groups beyond our discipline has enhanced the profile of the discipline in Australasia and could do the same in the UK.
© 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Mesh:

Year:  2012        PMID: 22360566      PMCID: PMC3391524          DOI: 10.1111/j.1365-2125.2012.04242.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

Review 1.  Quality use of medicines in the community: the Australian experience.

Authors:  A J Smith; P McGettigan
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

2.  An integrated national pharmaceutical policy for the United Kingdom?

Authors:  T Walley; A Earl-Slater; A Haycox; A Bagust
Journal:  BMJ       Date:  2000-12-16

3.  A prescription for better prescribing.

Authors:  Jeffrey K Aronson; Graeme Henderson; David J Webb; Michael D Rawlins
Journal:  BMJ       Date:  2006-09-02

4.  Construction and evaluation of a web-based interactive prescribing curriculum for senior medical students.

Authors:  Anthony Smith; Tina Tasioulas; Nicole Cockayne; Gary Misan; Graham Walker; Gary Quick
Journal:  Br J Clin Pharmacol       Date:  2006-12       Impact factor: 4.335

5.  Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial.

Authors:  H Asita de Silva; Arunasalam Pathmeswaran; Channa D Ranasinha; Shaluka Jayamanne; Senarath B Samarakoon; Ariyasena Hittharage; Ranjith Kalupahana; G Asoka Ratnatilaka; Wimalasiri Uluwatthage; Jeffrey K Aronson; Jane M Armitage; David G Lalloo; H Janaka de Silva
Journal:  PLoS Med       Date:  2011-05-10       Impact factor: 11.069

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.